A Look At Benzinga Pro's Most-Searched Tickers For June 6, 2019

This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform.

1. Rewalk Robotics Ltd. RWLK shares were down 22 percent to $5.77. On Wednesday, the FDA issued clearance for the company’s ReStore Exo-Suit.
2. ContraVir Pharmaceuticals, Inc. CTRV shares were up more than 130 percent to $11.32 after the company showed results from a preclinical study of CRV431 “significantly decreased the extent of fibrosis in a second animal model of liver fibrosis.”
3. InflaRX N.V. IFRX shares were up 4.46 percent to $3.19. On Wednesday, shares dropped on news of a failed mid-stage trial for skin inflammation drug. On Thursday, Baird downgraded the stock to Neutral and lowered the price target from $58 to $6.
4. Stitch Fix, Inc. SFIX shares were up 17 percent after the company reported better-than-expected third-quarter EPS and sales results. Net revenue increased 29 percent year over year.
5. Cloudera, Inc. CLDR shares were down 43.4 percent to $4.99 after the company reported worse-than-expected first-quarter sales results. The company also issued second-quarter EPS and sales guidance below analyst estimates.
6. Pivotal Software, Inc. PVTL shares were up 1.1 percent to $11.02. On Tuesday afternoon, the company issued sales guidance below analyst estimates, which dropped the stock by 40 percent.
7. Cronos Group Inc. CRON shares were down 1.5 percent to $15.74. Stifel Nicolaus initiated coverage on the stock with a Hold rating.
8. Sierra Oncology Inc. SRRA shares were down 5.15 percent to 74 cents. On Tuesday, the company announced FDA regulatory clarity for momeltonib and design of the MOMENTUM Phase 3 clinical trial.
9. Workhouse Group Inc. WKHS shares were up 7.8 percent to $2.34. On Wednesday, GM CEO Marry Barra defended plans to sell the Lordstown, Ohio assembly plant to Workhouse, citing “a lot of vetting.”
10. Roku, Inc. ROKU shares were down 1 percent to $100.69. On Wednesday, Guggenheim upgraded the stock from Neutral to Buy and raised the price target from $75 to $119.